Truist Financial Corp Raises Stock Position in Sanofi (NASDAQ:SNY)

Truist Financial Corp grew its holdings in Sanofi (NASDAQ:SNY - Free Report) by 6.2% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 595,139 shares of the company's stock after buying an additional 34,516 shares during the period. Truist Financial Corp's holdings in Sanofi were worth $33,006,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. GF Fund Management CO. LTD. raised its holdings in shares of Sanofi by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 7,710 shares of the company's stock valued at $428,000 after buying an additional 1,388 shares during the last quarter. Checchi Capital Advisers LLC raised its holdings in Sanofi by 9.9% during the first quarter. Checchi Capital Advisers LLC now owns 13,080 shares of the company's stock worth $725,000 after purchasing an additional 1,180 shares in the last quarter. Private Trust Co. NA raised its holdings in Sanofi by 19.8% during the first quarter. Private Trust Co. NA now owns 4,220 shares of the company's stock worth $234,000 after purchasing an additional 697 shares in the last quarter. Aaron Wealth Advisors LLC raised its holdings in Sanofi by 4.8% during the first quarter. Aaron Wealth Advisors LLC now owns 25,060 shares of the company's stock worth $1,390,000 after purchasing an additional 1,156 shares in the last quarter. Finally, First Bank & Trust raised its holdings in Sanofi by 13.3% during the first quarter. First Bank & Trust now owns 64,565 shares of the company's stock worth $3,581,000 after purchasing an additional 7,601 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.4%

NASDAQ SNY traded up $0.19 during mid-day trading on Tuesday, reaching $48.51. 265,218 shares of the stock were exchanged, compared to its average volume of 2,601,276. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The business's fifty day simple moving average is $50.52 and its 200 day simple moving average is $52.12. The stock has a market capitalization of $118.97 billion, a PE ratio of 17.32, a PEG ratio of 1.05 and a beta of 0.48. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. Sanofi's revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.78 earnings per share. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were paid a $2.0369 dividend. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Wall Street Analyst Weigh In

SNY has been the topic of several recent analyst reports. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Sanofi has an average rating of "Buy" and a consensus price target of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.